News stories about Corbus Pharmaceuticals (NASDAQ:CRBP) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Corbus Pharmaceuticals earned a news impact score of 0.13 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 46.3024523099335 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Here are some of the media headlines that may have effected Accern Sentiment Analysis’s analysis:

Shares of Corbus Pharmaceuticals (CRBP) opened at $6.75 on Wednesday. Corbus Pharmaceuticals has a 1-year low of $5.30 and a 1-year high of $10.50. The firm has a market capitalization of $391.37, a price-to-earnings ratio of -10.38 and a beta of 2.09.

Corbus Pharmaceuticals (NASDAQ:CRBP) last issued its earnings results on Monday, March 12th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by ($0.04). Corbus Pharmaceuticals had a negative return on equity of 85.97% and a negative net margin of 1,040.41%. analysts expect that Corbus Pharmaceuticals will post -0.73 EPS for the current year.

A number of research firms recently issued reports on CRBP. BidaskClub upgraded Corbus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, January 25th. Raymond James Financial began coverage on Corbus Pharmaceuticals in a report on Friday, January 19th. They set an “outperform” rating and a $24.00 price objective for the company. ValuEngine upgraded Corbus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, March 1st. Cantor Fitzgerald set a $28.00 price objective on Corbus Pharmaceuticals and gave the company an “overweight” rating in a report on Thursday, December 14th. Finally, Noble Financial reiterated a “buy” rating on shares of Corbus Pharmaceuticals in a report on Friday, December 15th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $25.75.

COPYRIGHT VIOLATION NOTICE: “Corbus Pharmaceuticals (CRBP) Earning Somewhat Favorable Media Coverage, Study Finds” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.

Insider Buying and Selling by Quarter for Corbus Pharmaceuticals (NASDAQ:CRBP)

Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with's FREE daily email newsletter.